

3 June 2024

**Hemogenyx Pharmaceuticals plc**  
("Hemogenyx Pharmaceuticals" or the "Company")

**Posting of Annual Report & Notice of Annual General Meeting**

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2023, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy will be posted to shareholders today and are available on the Company's website at <https://hemogenyx.com/investors/annual-half-year-reports/>.

The AGM is to be held on 27 June 2024 at 2.00 pm BST at the offices of SP Angel Corporate Finance LLP, Prince Frederick House, 35-39 Maddox Street, London W1S 2PP.

**Enquiries:**

**Hemogenyx Pharmaceuticals plc**

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Peter Redmond, Director

<https://hemogenyx.com>

[headquarters@hemogenyx.com](mailto:headquarters@hemogenyx.com)

[peter.redmond@hemogenyx.com](mailto:peter.redmond@hemogenyx.com)

**SP Angel Corporate Finance LLP**

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

**Peterhouse Capital Limited**

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

**About Hemogenyx Pharmaceuticals plc**

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAAMMTTMTTJBII